Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Isoform 1: Cytoplasm Nucleus Note=Shuttles between the cytoplasm and nucleus (PubMed:7565688, PubMed:24753571). Nuclear import is mediated by TNPO1 (PubMed:24753571). ; SUBCELLULAR LOCATION: Isoform 5: Cytoplasm Nucleus Nucleus, nucleolus Note=Predominantly nuclear but can shuttle between nucleus and cytoplasm. TNPO1 can mediate its nuclear import whereas XPO5 can mediate its nuclear export. |
Domain |
PF02137 Adenosine-deaminase (editase) domain PF00035 Double-stranded RNA binding motif PF02295 Adenosine deaminase z-alpha domain |
Function |
Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing (PubMed:7972084, PubMed:7565688, PubMed:12618436). This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication. |
Biological Process |
GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0001701 in utero embryonic development GO:0001933 negative regulation of protein phosphorylation GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001960 negative regulation of cytokine-mediated signaling pathway GO:0002200 somatic diversification of immune receptors GO:0002244 hematopoietic progenitor cell differentiation GO:0002262 myeloid cell homeostasis GO:0002566 somatic diversification of immune receptors via somatic mutation GO:0002683 negative regulation of immune system process GO:0006382 adenosine to inosine editing GO:0006397 mRNA processing GO:0006417 regulation of translation GO:0006469 negative regulation of protein kinase activity GO:0009451 RNA modification GO:0009615 response to virus GO:0010608 posttranscriptional regulation of gene expression GO:0016246 RNA interference GO:0016441 posttranscriptional gene silencing GO:0016458 gene silencing GO:0016553 base conversion or substitution editing GO:0017148 negative regulation of translation GO:0019058 viral life cycle GO:0019079 viral genome replication GO:0022613 ribonucleoprotein complex biogenesis GO:0022618 ribonucleoprotein complex assembly GO:0030099 myeloid cell differentiation GO:0030218 erythrocyte differentiation GO:0031047 gene silencing by RNA GO:0031050 dsRNA fragmentation GO:0031054 pre-miRNA processing GO:0031348 negative regulation of defense response GO:0033673 negative regulation of kinase activity GO:0034101 erythrocyte homeostasis GO:0034248 regulation of cellular amide metabolic process GO:0034249 negative regulation of cellular amide metabolic process GO:0034340 response to type I interferon GO:0034470 ncRNA processing GO:0035194 posttranscriptional gene silencing by RNA GO:0035195 gene silencing by miRNA GO:0035196 production of miRNAs involved in gene silencing by miRNA GO:0035280 miRNA loading onto RISC involved in gene silencing by miRNA GO:0035455 response to interferon-alpha GO:0040029 regulation of gene expression, epigenetic GO:0042326 negative regulation of phosphorylation GO:0043331 response to dsRNA GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043902 positive regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044387 negative regulation of protein kinase activity by regulation of protein phosphorylation GO:0045069 regulation of viral genome replication GO:0045070 positive regulation of viral genome replication GO:0045071 negative regulation of viral genome replication GO:0045088 regulation of innate immune response GO:0045824 negative regulation of innate immune response GO:0048524 positive regulation of viral process GO:0048525 negative regulation of viral process GO:0048872 homeostasis of number of cells GO:0050777 negative regulation of immune response GO:0050792 regulation of viral process GO:0051348 negative regulation of transferase activity GO:0051607 defense response to virus GO:0060147 regulation of posttranscriptional gene silencing GO:0060149 negative regulation of posttranscriptional gene silencing GO:0060216 definitive hemopoiesis GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060339 negative regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0060761 negative regulation of response to cytokine stimulus GO:0060966 regulation of gene silencing by RNA GO:0060967 negative regulation of gene silencing by RNA GO:0060968 regulation of gene silencing GO:0060969 negative regulation of gene silencing GO:0061484 hematopoietic stem cell homeostasis GO:0070918 production of small RNA involved in gene silencing by RNA GO:0070922 small RNA loading onto RISC GO:0071357 cellular response to type I interferon GO:0071359 cellular response to dsRNA GO:0071407 cellular response to organic cyclic compound GO:0071826 ribonucleoprotein complex subunit organization GO:0098542 defense response to other organism GO:0098586 cellular response to virus GO:1900368 regulation of RNA interference GO:1900369 negative regulation of RNA interference GO:1903900 regulation of viral life cycle GO:1903901 negative regulation of viral life cycle GO:1903902 positive regulation of viral life cycle |
Molecular Function |
GO:0003726 double-stranded RNA adenosine deaminase activity GO:0004000 adenosine deaminase activity GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016814 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines GO:0019239 deaminase activity |
Cellular Component |
GO:0005681 spliceosomal complex GO:0044530 supraspliceosomal complex |
KEGG |
hsa04623 Cytosolic DNA-sensing pathway |
Reactome |
R-HSA-75102: C6 deamination of adenosine R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-77042: Formation of editosomes by ADAR proteins R-HSA-74160: Gene Expression R-HSA-168256: Immune System R-HSA-913531: Interferon Signaling R-HSA-909733: Interferon alpha/beta signaling R-HSA-75072: mRNA Editing R-HSA-75064: mRNA Editing |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ADAR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ADAR in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ADAR in various data sets.
|
Points in the above scatter plot represent the mutation difference of ADAR in various data sets.
|
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAR. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ADAR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ADAR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ADAR |
Name | adenosine deaminase, RNA-specific |
Aliases | ADAR1; IFI4; G1P1; interferon-induced protein 4; AGS6; DRADA; DSRAD; K88DSRBP; P136; 136 kDa double-stranded ...... |
Chromosomal Location | 1q21.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ADAR collected from DrugBank database. |
There is no record. |